Business
END-TO-END INTEGRATE
AT D DRUG DISCOVERY
RY
Figure 4
Biotech-CRO alliance for drug development testing emerging model using 1-Program experiment
The accelerator: engaging academic PIs and CROs in close interaction and leveraging distributed expertise BioMotiv is a for-profit accelerator that is affiliat- ed with The Harrington Project for Discovery and Development, a non-profit dedicated to support- ing the creation of therapeutic breakthroughs based on the innovations of physician-scientists. BioMotiv addresses the limitations of traditional accelerators with an innovative model that pro- vides a novel link between academic projects and late-stage commercialisation partners. While tra- ditional accelerators do simplify the difficult and lengthy process of helping academic and scientific innovations become commercial products, most often these projects fail to make it to the next level. Typically, the tenure of resident start-ups is cut short due to the heavy burden on a small com- pany to continue to raise funds, manage opera- tions, forge partnerships and achieve the mile- stones needed to reach a value or partnering inflection point. To support its partners through these trials, BioMotiv engages with PIs and very early-stage therapeutics companies well before they become attractive to larger biotechs, biopharmaceutical companies or venture capital firms. BioMotiv pro-
28
vides resources and hands-on guidance while working closely together with the PI or scientific founder to continue to flesh out understanding of the pathway and drug candidate, a key to garner- ing interest from biotechs and biopharmaceutical companies down the road. In this model, BioMotiv provides tactical and strategic leadership as well as business development support for the early-stage company and secures CRO involvement, with Charles River playing a major role as a drug dis- covery and development partner, and brings diverse drug development expertise and consul- tants to pivotal early-stage studies. This type of active collaboration greatly energises a project, offers insights into the development path for these early-stage companies and leverages distributed expertise effectively.
The biotech and the CRO: an alliance integrating sources of expertise to accelerate drug development The biotech company Nimbus Therapeutics has developed extensive drug discovery and technolo- gy partnerships with leading industry, academic and government organisations. As part of Nimbus’ unique outsourcing model to design and develop breakthrough medicines, its team also
Drug Discovery World Winter 2017/18
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
